We are advised by Celltrion that journalists and other readers should disregard the news release, Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths, issued 21-May-2025 over PR Newswire.
SOURCE Celltrion
https://rt.newswire.ca/rt.gif?NewsItemId=CN93107&Transmission_Id=202505231201PR_NEWS_USPR_____CN93107A&DateId=20250523